Treatment of B-RAF mutant human tumor cells with a MEK inhibitor requires Bim and is enhanced by a BH3 mimetic
J. Clin. Invest. Mark S. Cragg, et al. 118:3651
doi:10.1172/JCI35437 [Go to this article.]

Problems with a PDF?